Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Apr 28  •  04:00PM ET
362.74
Dollar change
+6.61
Percentage change
1.86
%
Index
S&P 500
P/E
15.43
EPS (ttm)
23.50
Insider Own
0.30%
Shs Outstand
217.37M
Perf Week
10.55%
Market Cap
78.77B
Forward P/E
12.42
EPS next Y
29.21
Insider Trans
-0.03%
Shs Float
216.50M
Perf Month
26.66%
Enterprise Value
-
PEG
3.09
EPS next Q
6.30
Inst Own
94.71%
Perf Quarter
12.33%
Income
5.24B
P/S
0.39
EPS this Y
-11.61%
Inst Trans
2.10%
Perf Half Y
5.96%
Sales
200.41B
P/B
1.80
EPS next Y
9.09%
ROA
4.27%
Perf YTD
3.48%
Book/sh
201.97
P/C
-
EPS next 5Y
4.02%
ROE
12.14%
52W High
427.54 -15.16%
Perf Year
-12.34%
Cash/sh
-
P/FCF
12.21
EPS past 3/5Y
1.27% 6.99%
ROIC
7.02%
52W Low
273.71 32.53%
Perf 3Y
-22.60%
EV/EBITDA
-
Sales past 3/5Y
8.34% 10.32%
Gross Margin
-
Volatility
3.81% 2.90%
Perf 5Y
-3.34%
EV/Sales
-
EPS Y/Y TTM
-8.53%
Oper. Margin
3.81%
ATR (14)
10.54
Perf 10Y
151.90%
Quick Ratio
-
Sales Y/Y TTM
9.44%
Profit Margin
2.62%
RSI (14)
77.69
Current Ratio
1.48
EPS Q/Q
-16.70%
SMA20
13.04%
Beta
0.61
Debt/Eq
0.73
Sales Q/Q
2.64%
SMA50
16.85%
Rel Volume
0.89
Prev Close
356.13
Employees
97100
LT Debt/Eq
0.70
SMA200
11.81%
Avg Volume
1.98M
Price
362.74
IPO
Oct 30, 2001
Option/Short
Yes / Yes
Trades
Volume
1,759,482
Change
1.86%
Date Action Analyst Rating Change Price Target Change
Apr-08-26Initiated Evercore ISI In-line $345
Feb-03-26Downgrade RBC Capital Mkts Outperform → Sector Perform $358
Jan-08-26Upgrade Wolfe Research Peer Perform → Outperform $425
Dec-19-25Downgrade Deutsche Bank Buy → Hold $320
Oct-14-25Initiated Goldman Neutral
Jul-21-25Downgrade Argus Buy → Hold
Jul-18-25Downgrade Leerink Partners Outperform → Market Perform $310
Apr-15-25Downgrade Robert W. Baird Outperform → Neutral $529
Mar-17-25Upgrade Argus Hold → Buy $450
Jan-22-25Downgrade Stephens Overweight → Equal-Weight $520 → $440
Apr-23-26 08:03AM
03:02AM
Apr-22-26 12:45PM
07:55AM
06:07AM
06:00AM Loading…
06:00AM
Apr-21-26 09:17AM
Apr-14-26 04:59AM
Apr-11-26 08:16AM
Apr-08-26 09:42AM
Apr-07-26 06:03PM
11:04AM
09:48AM
04:36AM
Apr-06-26 05:51PM
04:58PM Loading…
04:58PM
Apr-02-26 11:54AM
Apr-01-26 06:33AM
Mar-31-26 09:00AM
04:58AM
Mar-30-26 04:30PM
Mar-29-26 10:29AM
Mar-10-26 01:41PM
Mar-09-26 11:56AM
Mar-03-26 10:00AM
04:25AM
Mar-02-26 05:05PM
04:38PM
04:37PM
04:01PM
01:19PM Loading…
01:19PM
12:30PM
12:12PM
11:19AM
10:53AM
09:25AM
07:35AM
Feb-27-26 05:45AM
Feb-26-26 03:02PM
Feb-25-26 12:42PM
12:14PM
Feb-24-26 10:06AM
08:45AM
Feb-20-26 11:55AM
Feb-19-26 04:02PM
Feb-18-26 04:50PM
07:09AM
Feb-17-26 06:01PM
Feb-15-26 11:40PM
Feb-11-26 11:02PM
09:47AM
07:04AM
Feb-10-26 05:15PM
12:31PM
08:00AM
Feb-09-26 02:08PM
Feb-06-26 01:32PM
01:23PM
11:31AM
10:41AM
09:50AM
Feb-04-26 06:46AM
12:38AM
Feb-03-26 12:36PM
09:34AM
03:08AM
Feb-02-26 11:18AM
10:47AM
Jan-31-26 07:48AM
Jan-29-26 02:44PM
09:13AM
02:19AM
12:37AM
Jan-28-26 04:32PM
04:02PM
01:35PM
01:01PM
12:35PM
12:21PM
11:15AM
10:20AM
10:09AM
10:06AM
09:30AM
07:42AM
07:10AM
06:41AM
06:26AM
06:17AM
06:00AM
Jan-27-26 05:33PM
05:12PM
04:54PM
04:44PM
04:44PM
04:38PM
04:34PM
04:17PM
04:13PM
03:27PM
Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHULMAN AMY WDirectorMar 12 '26Sale287.50267,475218Mar 23 04:10 PM
Kendrick Charles Morgan JREVP & President, CommercialMar 06 '26Sale284.923,196910,60411,791Mar 09 04:45 PM
CHARLES MORGAN KENDRICKOfficerMar 06 '26Proposed Sale284.923,196910,593Mar 06 04:17 PM
COLLIS STEVEN HDirectorMar 05 '26Buy289.843,000869,5203,639Mar 06 08:03 AM
DeVore Susan D.DirectorAug 19 '25Buy312.151,200374,5803,502Aug 21 04:20 PM
BOUDREAUX GAILPresident and CEOJul 18 '25Buy286.948,5002,438,951151,020Jul 18 01:42 PM